Continuum Advisory’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.25M Buy
2,448
+345
+16% +$350K 0.22% 97
2025
Q4
$2.26M Buy
2,103
+304
+17% +$291K 0.23% 98
2025
Q3
$1.37M Sell
1,799
-376
-17% -$280K 0.15% 137
2025
Q2
$1.7M Buy
2,175
+248
+13% +$193K 0.2% 103
2025
Q1
$1.59M Buy
1,927
+333
+21% +$277K 0.2% 107
2024
Q4
$1.23M Buy
1,594
+93
+6% +$77K 0.16% 131
2024
Q3
$1.18M Buy
1,501
+358
+31% +$322K 0.15% 145
2024
Q2
$1.03M Sell
1,143
-3
-0.3% -$2.4K 0.15% 148
2024
Q1
$884K Sell
1,146
-65
-5% -$46.3K 0.13% 165
2023
Q4
$706K Sell
1,211
-45
-4% -$26.3K 0.1% 225
2023
Q3
$674K Sell
1,256
-286
-19% -$147K 0.11% 225
2023
Q2
$723K Sell
1,542
-22
-1% -$9.23K 0.12% 215
2023
Q1
$537K Buy
1,564
+198
+14% +$66.8K 0.09% 254
2022
Q4
$500K Sell
1,366
-485
-26% -$172K 0.09% 254
2022
Q3
$598K Buy
1,851
+18
+1% +$5.7K 0.11% 206
2022
Q2
$594K Sell
1,833
-33
-2% -$9.91K 0.11% 228
2022
Q1
$545K Buy
1,866
+772
+71% +$199K 0.1% 231
2021
Q4
$302K Sell
1,094
-6
-0.5% -$1.52K 0.07% 244
2021
Q3
$254K Buy
1,100
+63
+6% +$15.5K 0.07% 249
2021
Q2
$238K Buy
+1,037
New +$208K 0.07% 241

Other funds holding LLY

Continuum Advisory's LLY Position: Q1 2026 in Review

Continuum Advisory increased its Eli Lilly (LLY) stake by 16% in Q1 2026, buying an estimated $350K and bringing the position to 2,448 shares worth $2.25M. The position accounts for 0.22% of the portfolio, ranked #97.

Continuum Advisory first reported a position in LLY in Q2 2021 and has held it in 20 quarters since. The position peaked at $2.26M in Q4 2025. 4,355 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Continuum Advisory held 2,448 shares of Eli Lilly worth $2.25M as of Q1 2026.
  • Continuum Advisory bought 345 Eli Lilly shares in Q1 2026, an estimated $350K.
  • Eli Lilly made up 0.22% of Continuum Advisory's portfolio in Q1 2026, its #97 holding.
  • Continuum Advisory first reported a position in Eli Lilly in Q2 2021 and has held it in 20 quarters since.
  • Continuum Advisory's Eli Lilly position peaked at $2.26M in Q4 2025.
  • 4,355 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Continuum Advisory's 13F filing for Q1 2026, filed 22 Apr 2026.